Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination (MASSIV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03576313
Recruitment Status : Active, not recruiting
First Posted : July 3, 2018
Last Update Posted : March 6, 2020
Sponsor:
Collaborators:
Institute of Tropical Medicine, Belgium
National Malaria Control Programme, The Gambia
Liverpool School of Tropical Medicine
Radboud University
University of Durham
Imperial College London
Information provided by (Responsible Party):
London School of Hygiene and Tropical Medicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 16, 2020
Estimated Study Completion Date : December 2021